NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February:

February 10-11: BIO CEO & Investor Conference 2025. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in one-on-one meetings at this conference, taking place in New York. Interested parties can request a meeting through the BIO Partnering™ system or contact Jessica Breu at: jessica.breu@imux.com.February 11-12: Oppenheimer 35th Annual Healthcare Life Sciences Conference. Dr. Vitt will participate in a fireside chat at this virtual conference on Wednesday, February 12 at 1:20 pm ET. A webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.Additional team members, including Jason Tardio, President and Chief Operating Officer, Glenn Whaley, Chief Financial Officer, and Jessica Breu, Vice President Investor Relations and Communications, will also be in attendance to participate in one-on-one meetings at the conference. To schedule a meeting, please contact your Oppenheimer representative or Jessica Breu at: jessica.breu@imux.com.February 19-22: 19th Congress of ECCO (European Crohn's and Colitis Organisation). Members of Immunic's medical, clinical and preclinical teams will attend this congress in Berlin, Germany, where two abstracts discussing clinical and preclinical data on IMU-856, Immunic's orally available and systemically acting small molecule modulator that targets Sirtuin 6 (SIRT6), will be presented as digital oral presentations. The presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.Presentation Title: Promising Effects of IMU-856, an Orally Available Epigenetic Modulator of Barrier Regeneration - Biomarker Findings from a Phase 1 Clinical StudyPresenting Author: Amelie Schreieck, Ph.D., Senior Manager Biomarker Development, ImmunicAbstract Number: EC25-1515Presentation Number: DOP012Presentation Time: 5:57 pm – 6:03 pm CETSession Name: Digital Oral Presentation (DOP) Session 2: Clinical Trials IISession Date: February 20, 2025Session Hall: A8Presentation Title: Preclinical Characterization of IMU-856, an Orally Available Epigenetic Modulator of Gut Barrier Function and RegenerationPresenting Author: Martina Wirth, Ph.D., Senior Manager Translational Pharmacology, ImmunicAbstract Number: EC25-1096Presentation Number: DOP116Presentation Time: 6:27 pm – 6:33 pm CETSession Name: Digital Oral Presentation (DOP) Session 13: Basic Science in IBDSession Date: February 21, 2025Session Hall: A1February 25-27: 7th Neuroimmunology Drug Development Summit. Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present an overview on Immunic's lead asset, vidofludimus calcium (IMU-838), at this summit in Boston. The presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.Presentation Title: Vidofludimus Calcium (IMU-838) Combines the Best of Two Worlds: Neuroprotection and Relapse Prevention in Multiple SclerosisPresentation Date: Thursday, February 27, 2025Presentation Time: 12:10 pm ETFebruary 27 - March 1: Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025. Members of Immunic's medical, clinical and preclinical teams will attend this meeting in West Palm Beach, Florida. Two abstracts have been accepted for poster presentations, which will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations. Additionally, the team will be available throughout the event at booth #322.Poster Title: Baseline Characteristics Across Major Clinical Trials in Progressive Multiple Sclerosis: Insights from ORATORIO, EXPAND, MS-STAT2, HERCULES, and CALLIPERPresenting Author: Robert J. Fox, Staff Neurologist, Mellon Center for Multiple Sclerosis, Vice-Chair for Research, Neurological Institute, Cleveland Clinic, Cleveland, OhioAbstract Number: 452Poster Number: P102Poster Session: 1Session Date: Thursday, February 27, 2025Session Time: 6:00 pm – 7:30 pm ET (even-numbered posters present from 6:00-6:45 pm; odd-numbered posters present from 6:45-7:30 pm)Poster Title: Vidofludimus Calcium Shows a Potential Neuroprotective Function in Multiple Sclerosis through its Activity on Nurr1 in Preclinical ModelsPresenting Author: Evelyn Peelen, Ph.D., Head of Research, ImmunicAbstract Number: 427Poster Number: P317Poster Session: 2Session Date: Friday, February 28, 2025Session Time: 6:00 pm – 7:30 pm ET (even-numbered posters present from 6:00-6:45 pm; odd-numbered posters present from 6:45-7:30 pm)